CVS Generic Drugs Suit Fails to Get Class Action California judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients. $96.5 Million Generic Payout Latest Trouble for Mylan February 15, 2017 By Christine Blank A $96.5 million settlement is the latest in a series of pricing and competition issues Mylan has faced in the past year. How New Biosimilars Will Impact the Market February 15, 2017 By Christine Blank More biosimilars are coming onto the market , including competitors for Remicade and Neulasta. CVS, Cigna on board with generic EpiPens January 19, 2017 By Christine Blank The urgent need for a less-expensive epinephrine auto-injector is now being addressed. Generics and biosimilars, key to Trump drug price concerns January 19, 2017 By Christine Blank If pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group. Issues about biosimilar substitution November 29, 2016 By Christine Blank At a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here. Pharmacy prices vary widely for generic heart drugs November 29, 2016 By Christine Blank The prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found. Generic drugs save U.S. $227 billion November 01, 2016 By Christine Blank Generic drugs produced $227 billion in savings for the U.S. healthcare system in 2015 Why Remicade biosimilar sales will grow in the U.S. November 01, 2016 By Christine Blank Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.